Total Payments
$53,243
2024 Payments
$7,199
Companies
12
Transactions
89
Medicare Patients
799
Medicare Billing
$74,814
Payment Breakdown by Category
Other$47,576 (89.4%)
Food & Beverage$2,464 (4.6%)
Consulting$1,950 (3.7%)
Travel$1,140 (2.1%)
Education$112.92 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,576 | 24 | 89.4% |
| Food and Beverage | $2,464 | 58 | 4.6% |
| Consulting Fee | $1,950 | 3 | 3.7% |
| Travel and Lodging | $1,140 | 1 | 2.1% |
| Education | $112.92 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $45,916 | 54 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $3,883 | 5 | $0 (2024) |
| PFIZER INC. | $2,153 | 4 | $0 (2024) |
| Celgene Corporation | $726.75 | 13 | $0 (2024) |
| Medtronic, Inc. | $177.31 | 2 | $0 (2022) |
| Janssen Biotech, Inc. | $136.43 | 2 | $0 (2022) |
| FUJIFILM Healthcare Americas Corporation | $105.81 | 1 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $52.18 | 3 | $0 (2022) |
| Lilly USA, LLC | $45.72 | 2 | $0 (2024) |
| Dova Pharmaceuticals | $19.50 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,199 | 14 | ABBVIE INC. ($3,029) |
| 2023 | $12,866 | 22 | AbbVie Inc. ($10,288) |
| 2022 | $20,894 | 35 | ABBVIE INC. ($20,513) |
| 2021 | $12,218 | 15 | AbbVie Inc. ($12,039) |
| 2020 | $47.31 | 2 | AbbVie Inc. ($47.31) |
| 2019 | $19.50 | 1 | Dova Pharmaceuticals ($19.50) |
All Payment Transactions
89 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/16/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $5.34 | General |
| Category: Neuroscience | ||||||
| 07/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/24/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,578.00 | General |
| Category: Neuroscience | ||||||
| 07/09/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $108.65 | General |
| Category: Neuroscience | ||||||
| 06/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $130.03 | General |
| Category: IMMUNOLOGY | ||||||
| 05/24/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.24 | General |
| Category: Neuroscience | ||||||
| 05/16/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $109.01 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 05/01/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,012.50 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 04/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Neuroscience | ||||||
| 04/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.55 | General |
| Category: IMMUNOLOGY | ||||||
| 03/27/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $5.14 | General |
| Category: Neuroscience | ||||||
| 01/26/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $30.71 | General |
| Category: Immunology | ||||||
| 01/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/21/2023 | AbbVie Inc. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $15.01 | General |
| 11/22/2023 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,973.00 | General |
| Category: Neuroscience | ||||||
| 11/01/2023 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $116.52 | General |
| Category: Neuroscience | ||||||
| 10/30/2023 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 09/29/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $5.44 | General |
| Category: Neuroscience | ||||||
| 09/23/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $31.89 | General |
| Category: IMMUNOLOGY | ||||||
| 09/22/2023 | AbbVie Inc. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/24/2023 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 08/14/2023 | FUJIFILM Healthcare Americas Corporation | FUJIFILM (Device) | Food and Beverage | In-kind items and services | $105.81 | General |
| Category: Medical Device | ||||||
| 06/21/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.30 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 129 | 141 | $72,630 | $15,625 |
| 2022 | 10 | 317 | 334 | $569,473 | $29,252 |
| 2021 | 10 | 353 | 367 | $480,335 | $29,938 |
Total Patients
799
Total Services
842
Medicare Billing
$74,814
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 50 | $11,900 | $4,776 | 40.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $10,915 | $4,312 | 39.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 16 | 16 | $16,864 | $3,289 | 19.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $15,878 | $1,713 | 10.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 21 | 21 | $17,073 | $1,534 | 9.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 63 | 64 | $197,760 | $7,425 | 3.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 23 | 23 | $80,040 | $4,301 | 5.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 52 | 54 | $125,820 | $4,297 | 3.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 40 | 54 | $11,610 | $3,454 | 29.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 27 | $16,200 | $2,785 | 17.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 18 | 18 | $46,620 | $2,426 | 5.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 12 | 12 | $42,753 | $2,186 | 5.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 13 | $7,150 | $1,255 | 17.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 15 | 15 | $23,700 | $914.97 | 3.9% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 54 | 54 | $17,820 | $205.76 | 1.2% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 54 | 54 | $159,300 | $5,798 | 3.6% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 51 | 53 | $118,190 | $4,204 | 3.6% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 20 | 20 | $66,600 | $4,064 | 6.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 46 | 54 | $11,570 | $3,949 | 34.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 29 | 29 | $15,160 | $3,259 | 21.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 29 | 29 | $14,890 | $3,036 | 20.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 19 | 19 | $10,530 | $1,944 | 18.5% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 12 | 12 | $29,640 | $1,783 | 6.0% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 20 | 20 | $30,200 | $1,566 | 5.2% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2021 | 73 | 77 | $24,255 | $335.25 | 1.4% |
About Dr. Sujaata Dwadasi, M.D
Dr. Sujaata Dwadasi, M.D is a Internal Medicine healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2014. The National Provider Identifier (NPI) number assigned to this provider is 1609295518.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sujaata Dwadasi, M.D has received a total of $53,243 in payments from pharmaceutical and medical device companies, with $7,199 received in 2024. These payments were reported across 89 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($47,576).
As a Medicare-enrolled provider, Dwadasi has provided services to 799 Medicare beneficiaries, totaling 842 services with total Medicare billing of $74,814. Data is available for 3 years (2021–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology, Gastroenterology
- Location Austin, TX
- Active Since 04/08/2014
- Last Updated 11/18/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1609295518
Products in Payments
- SKYRIZI (Biological) $22,387
- HUMIRA (Biological) $14,677
- RINVOQ (Biological) $7,304
- ZEPOSIA (Drug) $4,203
- VELSIPITY (Drug) $2,142
- EndoFlip (Device) $146.40
- FUJIFILM (Device) $105.81
- STELARA (Biological) $99.00
- ENTYVIO (Biological) $52.18
- LINZESS (Drug) $48.21
- REMICADE (Biological) $37.43
- BRAVO (Device) $30.91
- OMVOH (Drug) $30.71
- Doptelet (Drug) $19.50
- SUCRAID (Drug) $13.80
- INJECTAFER (Drug) $13.40
- XELJANZ (Drug) $11.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Austin
Dr. Andrew Brenner, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $126,872
Internal Medicine $126,872
John Dallas, Md, MD
Internal Medicine — Payments: $94,461
Internal Medicine $94,461
Omesh Verma, Md, MD
Internal Medicine — Payments: $93,276
Internal Medicine $93,276
Lindsay Harrison, Md, MD
Internal Medicine — Payments: $80,623
Internal Medicine $80,623
Dr. Steven Berkowitz, Md, MD
Internal Medicine — Payments: $79,153
Internal Medicine $79,153
Dr. Manoj Thangam, M.d, M.D
Internal Medicine — Payments: $76,243
Internal Medicine $76,243